

ESTIMATED ANNUALIZED BURDEN HOURS, GENERATION 3 COHORT AND OMNI GROUP 2 COHORT

Type of respondent	Number of respondents	Number of responses per respondent	Average time per response (in hours)	Total annual burden hour
<b>I. PARTICIPANT COMPONENTS—ANNUAL FOLLOW-UP</b>				
A. Records Request .....	3212	1	15/60	803
B. Health Status Update .....	3212	1	15/60	803
SUB-TOTAL: PARTICIPANT COMPONENTS .....	* 3212	.....	.....	1606
<b>II. NON-PARTICIPANT COMPONENTS—ANNUAL FOLLOW-UP</b>				
A. Informant contacts .....	160	1	10/60	27
B. Records Request .....	1060	1	15/60	265
SUB-TOTAL: NON-PARTICIPANT COMPONENTS .....	1220	.....	.....	292

\* Number of participants as reflected in Rows I.A. and I.B. above.

SUMMARY OF 3 TABLES COMBINED—TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent	Number of respondents	Number of responses per respondent	Average time per response (in hours)	Total annual burden hour
Participants .....	5564	1	36/60	3344
Non-Participants .....	3816	1	14.5/60	920
Totals .....	9380	.....	.....	4264

(NOTE: reported and calculated numbers differ slightly due to rounding.)

**Lynn Susulsk**,  
*NHLBI Project Clearance Liaison, National Institutes of Health.*  
**Michael Lauer**,  
*Director, DCVS, National Institutes of Health.*  
 [FR Doc. 2013-23060 Filed 9-20-13; 8:45 am]  
**BILLING CODE 4140-01-P**

*Time:* 9:00 a.m. to 11:00 a.m.  
*Agenda:* To review and evaluate grant applications.  
*Place:* Hilton Garden Inn Washington, DC/ Bethesda, 7301 Waverly Street, Bethesda, MD 21045.

*Contact Person:* Jose F. Ruiz, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892-9550, (301) 451-3086, [ruizjf@nida.nih.gov](mailto:ruizjf@nida.nih.gov).

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01) (PAS-12-122).

*Date:* October 15, 2013.

*Time:* 11:00 a.m. to 2:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hilton Garden Inn Washington, DC/ Bethesda, 7301 Waverly Street, Bethesda, MD 21045.

*Contact Person:* Jose F. Ruiz, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892-9550, (301) 451-3086, [ruizjf@nida.nih.gov](mailto:ruizjf@nida.nih.gov).

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel; Medications Development Centers of Excellence Cooperative Program.

*Date:* October 15-16, 2013.

*Time:* 2:00 p.m. to 1:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hilton Garden Inn Washington, DC/ Bethesda, 7301 Waverly Street, Bethesda, MD 21045.

*Contact Person:* Jose F. Ruiz, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on

Drug Abuse, NIH, Room 4228, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892-9550, (301) 451-3086, [ruizjf@nida.nih.gov](mailto:ruizjf@nida.nih.gov).  
 (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

*Dated:* September 17, 2013.

**Michelle Trout**,  
*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013-22992 Filed 9-20-13; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Drug Abuse; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel GOMED: Grand Opportunity in Medications Development for Substance-Related Disorders (U01).

*Date:* October 15, 2013.

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which